Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8 EUR | -2.44% | +76.60% | -90.17% |
04-24 | Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024 | |
03-15 | Vivoryon Therapeutics N.V Announces Resignation of Board of Directors | CI |
Sales 2023 | -3.62K -3.87K -310K | Sales 2024 * | - | Capitalization | 20.85M 22.3M 1.79B |
---|---|---|---|---|---|
Net income 2023 | -28M -29.94M -2.4B | Net income 2024 * | -18M -19.25M -1.54B | EV / Sales 2023 | -53,497 x |
Net cash position 2023 | 18.52M 19.81M 1.59B | Net cash position 2024 * | 19.55M 20.9M 1.67B | EV / Sales 2024 * | - |
P/E ratio 2023 |
-7.27
x | P/E ratio 2024 * |
-1.12
x | Employees | 15 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.56% |
Latest transcript on Vivoryon Therapeutics N.V.
1 day | -2.44% | ||
1 week | +76.60% | ||
Current month | +48.15% | ||
1 month | +51.23% | ||
3 months | -91.32% | ||
6 months | -89.40% | ||
Current year | -90.17% |
Managers | Title | Age | Since |
---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 31/12/11 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Director/Board Member | 56 | 30/08/18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 74 | 31/12/06 | |
Director/Board Member | 54 | 31/12/06 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 0.8 | -2.44% | 344,230 |
25/04/24 | 0.82 | -8.38% | 1,589,391 |
24/04/24 | 0.895 | +24.31% | 3,324,608 |
23/04/24 | 0.72 | +26.32% | 2,581,230 |
22/04/24 | 0.57 | +25.83% | 546,850 |
Real-time Euronext Amsterdam, April 26, 2024 at 04:35 pm
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-90.17% | 22.26M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- VVY Stock